GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » ROE %

Accuray (Accuray) ROE %

: -78.06% (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Accuray's annualized net income for the quarter that ended in Dec. 2023 was $-38.5 Mil. Accuray's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $49.3 Mil. Therefore, Accuray's annualized ROE % for the quarter that ended in Dec. 2023 was -78.06%.

The historical rank and industry rank for Accuray's ROE % or its related term are showing as below:

ARAY' s ROE % Range Over the Past 10 Years
Min: -55.71   Med: -33.94   Max: 6.74
Current: -28.11

During the past 13 years, Accuray's highest ROE % was 6.74%. The lowest was -55.71%. And the median was -33.94%.

ARAY's ROE % is ranked worse than
68.93% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ARAY: -28.11

Accuray ROE % Historical Data

The historical data trend for Accuray's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.36 6.74 -9.53 -8.76 -17.37

Accuray Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.18 4.50 -18.87 -22.71 -78.06

Competitive Comparison

For the Medical Devices subindustry, Accuray's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accuray ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's ROE % distribution charts can be found below:

* The bar in red indicates where Accuray's ROE % falls into.



Accuray ROE % Calculation

Accuray's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=-9.28/( (53.189+53.659)/ 2 )
=-9.28/53.424
=-17.37 %

Accuray's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-38.484/( (50.944+47.653)/ 2 )
=-38.484/49.2985
=-78.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Accuray  (NAS:ARAY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-38.484/49.2985
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-38.484 / 428.952)*(428.952 / 476.59)*(476.59 / 49.2985)
=Net Margin %*Asset Turnover*Equity Multiplier
=-8.97 %*0.9*9.6674
=ROA %*Equity Multiplier
=-8.07 %*9.6674
=-78.06 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-38.484/49.2985
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-38.484 / -34.972) * (-34.972 / -15.856) * (-15.856 / 428.952) * (428.952 / 476.59) * (476.59 / 49.2985)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.1004 * 2.2056 * -3.7 % * 0.9 * 9.6674
=-78.06 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Accuray ROE % Related Terms

Thank you for viewing the detailed overview of Accuray's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray (Accuray) Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters director
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043